Is Cronos (TSX:CRON) Headed Further Down in Price?

Analysts aren’t overly excited about the prospects for Cronos Group Inc (TSX:CRON)(NASDAQ:CRON), and you shouldn’t be either.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Things could be about to get even worse for Cronos Group Inc (TSX:CRON)(NASDAQ:CRON).

Since March, the stock has been plummeting, losing around half of its value during that time. The stock has been heavily overpriced for some time now — with plenty of room to continue falling, especially now that one analyst has adjusted their target for the stock.

Last week, an analyst from Cowen & Co. downgraded her 12-month price target for Cronos from $21 to just $17, about 19% less. However, one analyst still has a price target set as high as $27 for the stock.

Considering how badly pot stocks have been struggling lately and with investors down on the industry, however, $27 might be overly optimistic, especially as Cronos is still at a valuation of $5 billion.

Multiple brokerages have price targets of $17 or less for Cronos, and it was only a month ago that it was above that price. The challenge when setting these price targets is that so much can happen in a year, especially in the volatile cannabis industry. Even if Cronos is able to continue growing its sales, it may not be enough given the high multiples that it trades at today.

Profits have become more of a focus for cannabis investors

As of late, investors have shown to be more concerned about profits rather than just sales growth. Many cannabis companies have been going through lots of cash, which is an issue for shareholders who worry about dilution or the company having to take on debt in order to keep growing.

The very growth that once made pot stocks attractive is now leading to problems. The race for industry around expansion has seen companies spread themselves thin.

Take rival Aurora Cannabis for example, which prides itself on having sales and operations in over 20 countries. With a net loss of over $158 million in its most recent quarter and $55 million in cash used from its operating activities, it’s financials have left a lot to desired.

In order for Cronos to be able to make it back to over $20 a share, a lot has to go right for the stock, and that just hasn’t been the case lately. While its net income has gotten a boost from non-operational items,  at the operational level, Cronos is just not achieving strong enough results to be a good buy.

Bottom line

Cronos is still a very expensive stock today, and a $17 price target may be as good as the company deserves. I’d argue that it should be even lower than that given that competition is growing more intense and things aren’t going to get any easier for Cronos from here on out.

Buying it would be a very risky proposition. While pot stocks may rebound from this latest series of sell-offs, Cronos is not one I’d expect to outperform its peers.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »